Literature DB >> 29451958

Peripartum cardiomyopathy: Status 2018.

Divya Gupta1, Nanette K Wenger2.   

Abstract

Peripartum cardiomyopathy is a rare cardiac condition, overall. However, in certain populations can be found frequently enough and the signs, symptoms, and management should be readily understood. Here we provide an updated overview of this topic.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Cardiomyopathy; Peripartum; outcomes

Mesh：

Year:  2018        PMID： 29451958      PMCID： PMC6490057          DOI： 10.1002/clc.22888

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN： 0160-9289            Impact factor:   2.882


  29 in total

1.  Incidence, mortality, and racial differences in peripartum cardiomyopathy.

Authors:  Somjot S Brar; Steven S Khan; Gagandeep K Sandhu; Michael B Jorgensen; Neil Parikh; Jin-Wen Y Hsu; Albert Yuh-Jer Shen
Journal:  Am J Cardiol       Date:  2007-06-06       Impact factor: 2.778

Review 2.  Autoimmune mechanisms as the basis for human peripartum cardiomyopathy.

Authors:  Aftab A Ansari; James D Fett; Robert E Carraway; Ann E Mayne; Nattawat Onlamoon; J Bruce Sundstrom
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

Review 3.  Peripartum cardiomyopathy: Status 2018.

Authors:  Divya Gupta; Nanette K Wenger
Journal:  Clin Cardiol       Date:  2018-02-16       Impact factor: 2.882

Review 4.  Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline.

Authors: 
Journal:  J Card Fail       Date:  2006-02       Impact factor: 5.712

5.  Risk stratification of women with peripartum cardiomyopathy at initial presentation: a dobutamine stress echocardiography study.

Authors:  Sharmila Dorbala; Susan Brozena; Sophia Zeb; Kathleen Galatro; Peter Homel; Jian-Fang Ren; Farooq A Chaudhry
Journal:  J Am Soc Echocardiogr       Date:  2005-01       Impact factor: 5.251

6.  Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation.

Authors:  Uri Elkayam; Mohammed W Akhter; Harpreet Singh; Salman Khan; Fahed Bitar; Afshan Hameed; Avraham Shotan
Journal:  Circulation       Date:  2005-04-26       Impact factor: 29.690

7.  MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.

Authors:  Julie Halkein; Sebastien P Tabruyn; Melanie Ricke-Hoch; Arash Haghikia; Ngoc-Quynh-Nhu Nguyen; Michaela Scherr; Karolien Castermans; Ludovic Malvaux; Vincent Lambert; Marc Thiry; Karen Sliwa; Agnes Noel; Joseph A Martial; Denise Hilfiker-Kleiner; Ingrid Struman
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

8.  Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital.

Authors:  Simeon A Isezuo; Sani A Abubakar
Journal:  Ethn Dis       Date:  2007       Impact factor: 1.847

9.  Cardiac angiogenic imbalance leads to peripartum cardiomyopathy.

Authors:  Ian S Patten; Sarosh Rana; Sajid Shahul; Glenn C Rowe; Cholsoon Jang; Laura Liu; Michele R Hacker; Julie S Rhee; John Mitchell; Feroze Mahmood; Philip Hess; Caitlin Farrell; Nicole Koulisis; Eliyahu V Khankin; Suzanne D Burke; Igor Tudorache; Johann Bauersachs; Federica del Monte; Denise Hilfiker-Kleiner; S Ananth Karumanchi; Zoltan Arany
Journal:  Nature       Date:  2012-05-09       Impact factor: 49.962

10.  Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study.

Authors:  Denise Hilfiker-Kleiner; Arash Haghikia; Dominik Berliner; Jens Vogel-Claussen; Johannes Schwab; Annegret Franke; Marziel Schwarzkopf; Philipp Ehlermann; Roman Pfister; Guido Michels; Ralf Westenfeld; Verena Stangl; Ingrid Kindermann; Uwe Kühl; Christiane E Angermann; Axel Schlitt; Dieter Fischer; Edith Podewski; Michael Böhm; Karen Sliwa; Johann Bauersachs
Journal:  Eur Heart J       Date:  2017-09-14       Impact factor: 29.983
View more
  1 in total

Review 1.  Peripartum cardiomyopathy: Status 2018.

Authors:  Divya Gupta; Nanette K Wenger
Journal:  Clin Cardiol       Date:  2018-02-16       Impact factor: 2.882
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.